ViewRay Announces Publicatiat Of Retrospective Study at MR-guided Radiatiat Treatment 4 Locally Advanced Pancreatic Cancer #Entertain_MentApril 15, 2019
CLEVELAND, April 11, 2019 /PRNewswire/ –ViewRay, Inc. (Nasdaq: VRAY ) announced today the publication of a retrospective analysis of outcomes for the stereotactic treatment of locally advanced pancreatic cancer using precise, high-dose MRI-guided radiation therapy delivered with MRIdian’s on-table adaptive dose planning system.
Daily MRI guidance enabled by MRIdian allows clinicians to assess the position of the target relative to sensitive organs and adjust the treatment plan at the moment of treatment in order to minimize radiation exposure to healthy tissues and allow for an increased dose to be delivered to the disease.
“Locally advanced pancreatic cancer is notoriously difficult to treat, and the outcomes noted in this retrospective study are better than expected and very encouraging.
According to the publication, “The study was a multi‐institutional, retrospective, cohort study based on data from 5 institutions.
Eligible patients had biopsy‐proven, inoperable, pancreatic cancer treated with MRgRT from 2014 through 2016.
The SMART trial is designed to enroll 133 participants with borderline resectable or inoperable locally advanced pancreatic cancer.
In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
ViewRay, Inc. (Nasdaq: VRAY ), designs, manufactures and markets the MRIdian® radiation therapy system.
For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business in general, see ViewRay’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as updated periodically with the company’s other filings with the SEC.
These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.